Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
about
Targeted therapy of gastrointestinal stromal tumoursReview article: the biology, diagnosis and management of gastrointestinal stromal tumoursThe GIST of targeted therapy for malignant melanomaA potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functionsMolecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Rare cystic liver lesions: a diagnostic and managing challenge.[Hemato-oncological diseases].Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib.UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trialNCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.[Rectal stromal tumor: report of a case]Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumorsRecent advances in the management of gastrointestinal stromal tumors.Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry.Is there something other than imatinib mesilate in therapeutic options for GIST?Updates on the management of gastrointestinal stromal tumors.Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.Clinical and therapeutic considerations of GISTExternal beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors.Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.A gist of gastrointestinal stromal tumors: A review.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelinesImatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors.A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan.Relationship of preoperative neutrophil lymphocyte ratio with prognosis in gastrointestinal stromal tumors.Successful treatment of gastrointestinal stromal tumor with multiple liver metastases with radiofrequency ablation and imatinib: A case report.Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose.Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)Recent advances and novel agents for gastrointestinal stromal tumor (GIST)Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.State of the Art in the Treatment of Gastrointestinal Stromal Tumors.
P2860
Q26745633-7EE5B83C-10B7-424F-8AB4-9F1C3176CCD0Q26825310-20756AA1-1C4D-4777-B5FA-9790F1311634Q26827092-C3C51107-17B6-4F34-8B73-3B2B67B768FFQ27851995-1E46EE08-AD21-4C96-ADCB-F084DD5189D2Q27853181-9579A345-6A96-4F3A-9B92-FED16BA87B13Q28078946-8A54B78E-CF0E-4178-99CF-C7678D1477B5Q30245586-06205F38-0795-4898-88E9-930A32BB43E8Q30446819-98B315CF-51F1-46FC-B79D-C2CD899218EBQ33410075-E823B8DB-0629-44F5-8D19-3000BA49B043Q33575310-50CE15C7-9305-4386-B14B-3DA5F6F1BE23Q33612778-5061CD90-EF8D-4BDD-96AC-BFC6E0659788Q33633409-54AF3EDA-FADA-4932-8E04-625E96C09410Q33699901-FEC90079-45C4-4256-B836-4839A90F6D0DQ33921067-6EBDBF14-2DE0-4357-B8AC-40522DF3C712Q33991886-F89B3FAD-3CA4-4CEE-B3A7-4C710087D702Q34083140-06B20E63-A2FA-4BAC-99C5-289BA967904EQ34100865-DBAD5388-C015-4C83-BDE4-6D3EFB377B4FQ34175620-9212460C-090D-4F10-A63D-F2F79C0B045FQ34202009-215E96EB-49D9-45D3-B0C8-5D80DCECCDC4Q34207379-91BAB16D-B74F-4492-B6F7-D57260431219Q34256921-78B50EFE-CF1B-471C-BB08-E38C3E5CD856Q34339623-762E289B-0F51-4144-B8F0-25C02FE6E932Q34341168-441B5CA3-7A90-47F7-9128-FAEDD9D01F37Q34461532-E12289FF-C5FE-4A6C-8153-4633DBBE6FC7Q34636081-A4C535E6-E1F7-4482-8C95-A09BA4463FD4Q34654203-C99E5956-EF9B-4CD3-A7BD-5892F1C9EB17Q34662946-C60A2A9B-ED6B-4A96-8418-B30833275737Q34664305-D5EE0F85-D838-4578-A15C-6D5B32D59CBCQ34672344-9D7D04F9-E5DD-4F2F-B7D0-7DBBDC9F9F1BQ35607790-61041EFA-5D30-496A-A10C-B5733FB36090Q35616803-BCEBB4FC-739C-44AC-81D5-B79182D5A234Q35626506-091D2DAA-500A-45C6-9B9A-81B0447714C5Q35799223-7F6978A7-123B-43B8-AF87-FD35079A547EQ35871522-8E77EE50-48D3-4BFF-8525-DA3A3F86FEE8Q35905878-8CA055C2-DFE4-4D11-93A1-386566C568EDQ35947339-DB6C0575-8048-47A9-AD95-376120357B12Q35994305-4B832E08-EBF1-4C62-B230-1C822AF1A98CQ36118178-7FBF90B7-5777-43A2-B423-3588E3181278Q36180074-C84156B0-B62E-45C2-B364-8DF70D74A7E0Q36344557-78D26027-2A29-4BBE-B702-73F653A3C47A
P2860
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Comparison of two doses of ima ...... ta-analysis of 1,640 patients.
@ast
Comparison of two doses of ima ...... ta-analysis of 1,640 patients.
@en
type
label
Comparison of two doses of ima ...... ta-analysis of 1,640 patients.
@ast
Comparison of two doses of ima ...... ta-analysis of 1,640 patients.
@en
prefLabel
Comparison of two doses of ima ...... ta-analysis of 1,640 patients.
@ast
Comparison of two doses of ima ...... ta-analysis of 1,640 patients.
@en
P2860
P356
P1476
Comparison of two doses of ima ...... ta-analysis of 1,640 patients.
@en
P2093
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)
P2860
P304
P356
10.1200/JCO.2009.24.2099
P407
P577
2010-02-01T00:00:00Z